Anbio Biotechnology Key Ratios
₹7.70
₹-0.02
(-0.26%)
As on 27-Aug-2026 10:37EDT
Market cap
₹299 Mln
Revenue (TTM)
₹9 Mln
P/E Ratio
48.6
P/B Ratio
10.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 5.64 | -28.39 | -- |
| EBIT | -- | -- | -- | -- | -- |
| Net Profit | -- | -- | 169.86 | -13.84 | -- |
| EPS | -- | -- | 160.01 | -- | -- |
| Book Value | -- | -- | 69.00 | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-25 | Dec-24 | Dec-23 |
| EBIT-Margin
| 28.98 | -- | -- | 24.38 | 33.58 |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| 19.45 | -- | 27.05 | 14.83 | 16.47 |
| Return on Capital
| 19.45 | -- | 27.05 | 14.83 | 16.47 |
| Return on Assets
| 18.28 | -- | 26.05 | 13.66 | 15.14 |
| Debt to Equity (x)
| -- | -- | -- | -- | -- |
Profitability
ROCE
27.05
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
27.05
|
14.83
|
16.47
|
132.75
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
27.05
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
27.05
|
14.83
|
16.47
|
132.75
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
26.05
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
26.05
|
13.66
|
15.14
|
106.08
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
--
|
24.38
|
33.58
|
42.55
|
55.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
74.06
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
74.06
|
28.99
|
33.58
|
42.52
|
57.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
0.06
--
Year on year growth in net sales
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
0.06
|
0.22
|
-0.71
|
4.32
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
--
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
--
|
-11.46
|
-77.51
|
307.97
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
169.86
--
Year on year growth in profit after tax
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
169.86
|
5.29
|
-77.49
|
294.79
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
1.60
--
Year on year growth in earnings per share
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
1.60
|
0.05
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Current Ratio
344.31
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
344.31
|
10.71
|
15.86
|
9.88
|
2.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
--
|
--
|
15.86
|
9.63
|
2.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
--
|
--
|
--
|
1,252.55
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
42.29
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
42.29
|
13.01
|
28.08
|
0.02
|
16.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.35
--
Sales / Average Total Assets
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
0.35
|
0.47
|
0.45
|
2.49
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
99.72
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
99.72
|
65.81
|
51.38
|
5.59
|
59.18
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
--
|
--
|
19.28
|
5.89
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
268.93
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
268.93
|
194.75
|
121.81
|
54.85
|
365.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Anbio Biotechnology
|
--
|
-128.93
|
-51.14
|
-43.37
|
-306.72
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
